<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939831</url>
  </required_header>
  <id_info>
    <org_study_id>FUOBGY2021-05</org_study_id>
    <nct_id>NCT04939831</nct_id>
  </id_info>
  <brief_title>Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IB3,IIA2)</brief_title>
  <acronym>LAUNCH 3</acronym>
  <official_title>A Multicenter Noninferior Randomized Controlled Study Comparing the Efficacy of Laparoscopic Versus Abdominal Radical Hysterectomy for Cervical Cancer(Stage IB3,IIA2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Obstetrics &amp; Gynecology Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taizhou Hospital, Affiliated Cancer Hospital of the University of Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Obstetrics &amp; Gynecology Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm whether there is a difference between laparoscopic&#xD;
      radical hysterectomy (LRH) and abdominal radical hysterectomy (ARH) in patient survival for&#xD;
      Cervical Cancer (Stage IB3, IIA2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare LRH (or robotic-assisted) and ARH in patients with&#xD;
      cervical cancer (Stage IB3, IIA2), by a multicenter stratified randomized controlled study,&#xD;
      mainly including the following aspects:&#xD;
&#xD;
        1. To compare the differences in PFS and OS between patients receiving LRH and ARH.&#xD;
&#xD;
        2. To investigate whether PFS and OS in LRH can be improved by more rigorous specification&#xD;
           of surgical details (including tumor-free principles and standard surgical scopes).&#xD;
&#xD;
        3. To assess postoperative complications and quality of survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of OS at 5 years</measure>
    <time_frame>5 years from surgery</time_frame>
    <description>Compare between groups(Cox proportional hazards model will be used to estimate the hazard ratio and 95% CI for the effect of treatment on the 5-year OS rate.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the rate of PFS at 5 years</measure>
    <time_frame>5 years from surgery</time_frame>
    <description>The curves of PFS at 5 years will be estimated using the Kaplan-Meier method. The logrank test will be used to test the above hypothesis, the 5-year PFS rate difference and its 95% confidence interval (CI) for the comparison between the two groups will be estimated.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Analysis of continuous outcomes</measure>
    <time_frame>1 years from surgery</time_frame>
    <description>Compare these between groups(The continuous outcomes include operative duration(min), anesthesia time(min), blood loss during operation(ml), postoperative pain score and postoperative hospital stay(day). The outcomes with normal distribution will be summarised using mean and standard deviation (SD), while the outcomes with non-normal distribution will be summarised using median and interquartile. The differences in the outcomes and 95% CIs will be analysed by generalised linear model (GLM) with treatment as fixed effect and with normal distribution and identity link function.)</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of binary outcomes</measure>
    <time_frame>5 years from surgery</time_frame>
    <description>Compare these between groups(The intraoperative complications, postoperative complications, one-month and one-year postoperative quality of life and sexual life will be treated as binary outcomes and will be summarised by number (%) of participants with the event. The differences in the outcomes and 95% CIs will be analysed by GLM with treatment as fixed effect and with binomial distribution and identity link function.)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety analysis</measure>
    <time_frame>5 years from surgery</time_frame>
    <description>Adverse events (AEs) will be summarised using the number of AEs, the number (%) of participants with AEs by groups.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1104</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the group of LRH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the group of ARH</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Total Laparoscopic or Robotic Radical Hysterectomy</intervention_name>
    <description>Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Total Abdominal Radical Hysterectomy</intervention_name>
    <description>Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of squamous carcinoma of the cervix, adenocarcinoma, squamous&#xD;
             adenocarcinoma (Stage IB3,IIA2).&#xD;
&#xD;
          2. Age ≥ 21 years and ≤ 70 years.&#xD;
&#xD;
          3. Surgery type B and C (refer to Q-M surgical staging)&#xD;
&#xD;
          4. Normal range of liver and kidney function and blood count (specific details below)&#xD;
             Hemoglobin &gt; 60g/L Platelets &gt; 70*109/L Leukocytes &gt; 3*109/L Creatinine &lt; 50mg/dL&#xD;
             Transaminase abnormal indicators ≤ 3 Maximum value of transaminases not exceeding 3&#xD;
             times the corresponding normal value.&#xD;
&#xD;
          5. No history of other malignancies.&#xD;
&#xD;
          6. Non-pregnancy.&#xD;
&#xD;
          7. Physical strength classification: Karnofsky score ≥ 60;&#xD;
&#xD;
          8. Subjects voluntarily joined the study, signed the informed consent form, were&#xD;
             compliant and cooperated with the follow-up.&#xD;
&#xD;
          9. No psychiatric disorders and other serious immune system disorders (e.g. lupus&#xD;
             erythematosus, myasthenia gravis, HIV infection, etc.) (Note: Maximum diameter&#xD;
             measurement of cervical lesions is based on PET-CT, or CT, or MRI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who are contraindicated for various surgeries and cannot undergo surgery.&#xD;
&#xD;
          2. Patients who have received pelvic/abdominal radiotherapy irradiation or neoadjuvant&#xD;
             chemotherapy for cervical cancer.&#xD;
&#xD;
          3. Patients with recurrent cervical cancer&#xD;
&#xD;
          4. Patients with CT, MRI or PET-CT suggesting suspicious metastasis of pelvic lymph nodes&#xD;
             with maximum diameter &gt;2cm after further improvement of preoperative examination.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hua Jiang, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Obstetrics and Gynecology Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Jiang, PHD</last_name>
    <phone>(021)33189900-6529</phone>
    <email>jianghua@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xin Wu, PHD</last_name>
    <phone>(021)33189900-6529</phone>
    <email>wuxin_fc@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Obstetrics and Gynecology Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hua Jiang, PHD</last_name>
      <phone>(86)13601978182</phone>
      <email>jianghua@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical Cancer</keyword>
  <keyword>Abdominal Radical Hysterectomy</keyword>
  <keyword>Laparoscopic Radical Hysterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT04939831/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

